Clinical Trial

HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Overall, although there are many options for second-line treatment of liver cancer, the ORR is mostly limited to within 20-30%, with a median PFS of 3-5 months and a median OS of 10-20 months. The overall situation is still unsatisfactory, with low objective tumor response rates and targeted immune resistance being the main reasons affecting treatment efficacy. Increasing local treatment or overcoming resistance is currently a hot research topic. The aim of this study is to explore the effectiveness and safety of HAIC combined with TQB2450 and anlotinib for second-line treatment of advanced HCC patients.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06475287
Lead Sponsor Fudan University
Conditions Hepatocellular Carcinoma
Enrollment 42 participants
Start Date 2024-07-20
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-26